TheraRadar
← Back
Data updated: Mar 29, 2026

SHANGHAI HENLIUS BIOTECH

OncologyImmunologyOphthalmology
Biotech

SHANGHAI HENLIUS BIOTECH is a biotechnology company focused on Oncology, Immunology, Ophthalmology.

2025
Since
3
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

POHERDY 2025-11-13
BILPREVDA 2025-10-29
Efficacy
BILPREVDA 2025-08-29
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 83%
2 drugs Phase 3: 15 Phase 2: 22 Phase 1: 17
Immunology 7%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Ophthalmology 6%
0 drugs Phase 3: 2 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 2: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Ophthalmology
AbbVie big-pharma
Immunology, Oncology, Ophthalmology
ASTELLAS specialty
Oncology, Gastroenterology, Ophthalmology, Immunology
Roche big-pharma
Oncology, Ophthalmology, Immunology